V
Vast Therapeutics
Vast Therapeutics is an innovative, preclinical-stage pharmaceutical company
About Vast Therapeutics
Vast Therapeutics is a development stage pharmaceutical company focused on creating therapies to combat resistant bacteria and enhance respiratory health. The company operates in the biotechnology and pharmaceutical markets, targeting patients suffering from severe respiratory diseases. Vast Therapeutics primarily serves healthcare providers and patients who require advanced treatments for conditions like Nontuberculous Mycobacteria (NTM) infections.
The business model revolves around the research and development of innovative drug candidates, such as BIOC11, which has shown promising results in eradicating 99% of NTM in animal models. The company generates revenue through equity financing and aims to commercialize its therapies upon successful clinical trials and regulatory approvals.
Vast Therapeutics is a subsidiary of KNOW Bio, LLC, and benefits from the conglomerate's resources and expertise in biotechnology and MedTech. The company recently secured $30 million in equity financing from Reedy Creek Investments, LLC, which will support its ongoing research and development efforts.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Morrisville, United States
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 66.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Jan 2025 | $2M | — | National Institutes of Health | ↗ |
| GRANTOther financing | Nov 2022 | $1.2M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Vast Therapeutics is 1.9K monthly website visits, up 93.9% over the last three months. Vast Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
Mitotype Precision LabsHigh-throughput mitochondrial assays for drug discovery |
Sheffield, United Kingdom | Operational | 8 | $1.4M | $3.3M |
Draig TherapeuticsTargeted neuromodulators for major neuropsychiatric disorders treatment |
Cardiff, United Kingdom | Operational | |||
Amphista TherapeuticsNext-generation therapeutics for targeted protein degradation |
Great Abington, United Kingdom | Operational | |||
Leucid BioNext-generation CAR-T cell therapies for refractory cancers |
London, United Kingdom | Operational | |||
ExpanestheticsExpanesthetics is developing new and better analgesics and general anesthetics |
Davis, United States | Operational | |||
AutolusProgrammed T-cell immunotherapies for cancer and autoimmune diseases |
London, United Kingdom | Operational | |||
Z FactorTherapeutic agents for alpha-1-antitrypsin deficiency treatment |
Babraham, United Kingdom | Acquired | |||
WaveBreakSmall-molecule therapeutics for neurodegenerative diseases |
Cambridge, United Kingdom | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Vast Therapeutics in the Morrisville ecosystem
The Vast Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Series A2 investors entered at this stage
Victory Pharma
Cystic Fibrosis Foundation
Other known investors1 additional known investor
University of North Carolina at Chapel Hill
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vast Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vast Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










